Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $256.1 million versus the consensus estimate of $217.85 million.

FY 2026 Outlook:-
Revenue between $1.1 billion – $1.2 billion vs consensus $999.5 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.